Optical control of insulin release using a photoswitchable sulfonylurea

Nature Communications

Volumn 5, Issue , 2014, Pages

  Broichhagen, Johannes ^a   Schönberger, Matthias ^a   Cork, Simon C ^b   Frank, James A ^a   Marchetti, Piero ^c   Bugliani, Marco ^c   Shapiro, A M James ^d   Trapp, Stefan ^b   Rutter, Guy A ^e   Hodson, David J ^e   Trauner, Dirk ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF ALBERTA   (Canada)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INSULIN; JB 253; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLUE LIGHT; CONTROLLED STUDY; DRUG DESIGN; DRUG SENSITIVITY; EMBRYO; FEMALE; HORMONE DETERMINATION; HUMAN; HUMAN CELL; INSULIN RELEASE; MALE; NONHUMAN; OPTICS; PANCREAS ISLET BETA CELL; RODENT; ULTRAVIOLET RADIATION; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; LIGHT; METABOLISM; MOUSE; PANCREAS ISLET; RADIATION RESPONSE; SECRETION (PROCESS); SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

RODENTIA;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KATP CHANNELS; LIGHT; MALE; MICE; MICE, INBRED C57BL; SULFONYLUREA COMPOUNDS;

EID: 84925348891     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6116     Document Type: Article

References (60)

1. Currie, C. J., Poole, C. D. & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777 (2009).
2. Stitt, A. W. AGEs and diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 51, 4867-4874 (2010).
3. Prentki, M. & Nolan, C. J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 116, 1802-1812 (2006).
4. Turner, R. C., Cull, C. A., Frighi, V. & Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281, 2005-2012 (1999).
5. Fineman, M. S. et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26, 2370-2377 (2003).
6. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364-1379 (2012).
7. Ashcroft, F. M. & Gribble, F. M. Correlating structure and function in ATP-sensitive K+ channels. Trends Neurosci. 21, 288-294 (1998).
8. Aguilar-Bryan, L. et al. Toward understanding the assembly and structure of KATP channels. Physiol. Rev. 78, 227-245 (1998).
9. Miki, T., Nagashima, K. & Seino, S. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. J. Mol. Endocrinol. 22, 113-123 (1999).
10. Ashcroft, F. M. & Gribble, F. M. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 42, 903-919 (1999).
11. Seino, S. & Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 81, 133-176 (2003).
12. Rutter, G. A. Nutrient-secretion coupling in the pancreatic islet beta-cell: recent advances. Mol. Aspects Med. 22, 247-284 (2001).
13. Rorsman, P., Braun, M. & Zhang, Q. Regulation of calcium in pancreatic alpha- and beta-cells in health and disease. Cell Calcium 51, 300-308 (2012).
14. Henquin, J. C. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 52, 739-751 (2009).
15. Tsuboi, T. & Rutter, G. A. Multiple forms of 'kiss-and-run' exocytosis revealed by evanescent wave microscopy. Curr. Biol. 13, 563-567 (2003).
16. Cheatham, B. & Kahn, C. R. Insulin action and the insulin signaling network. Endocr. Rev. 16, 117-142 (1995).
17. Jennings, A. M., Wilson, R. M. & Ward, J. D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12, 203-208 (1989).
18. Evans, J. M., Ogston, S. A., Emslie-Smith, A. & Morris, A. D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49, 930-936 (2006).
19. Nathan, D. M. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963-1972 (2006).
20. Lam, T. K. Neuronal regulation of homeostasis by nutrient sensing. Nat. Med. 16, 392-395 (2010).
21. Hernandez-Sanchez, C. et al. Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death. Proc. Natl Acad. Sci. USA 98, 3549-3554 (2001).
22. Engler, R. L. & Yellon, D. M. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 94, 2297-2301 (1996).
23. Quayle, J. M., Nelson, M. T. & Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 77, 1165-1232 (1997).
24. Fortin, D. L. et al. Photochemical control of endogenous ion channels and cellular excitability. Nat. Methods 5, 331-338 (2008).
25. Fehrentz, T., Schonberger, M. & Trauner, D. Optochemical genetics. Angew. Chem. Int. Ed. 50, 12156-12182 (2011).
26. Grell, W. et al. Repaglinide and related hypoglycemic benzoic acid derivatives. J. Med. Chem. 41, 5219-5246 (1998).
27. Takahashi, T. et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci. Signal 6, ra94 (2013).
28. Zhang, C. L. et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325, 607-610 (2009).
29. Herbst, K. J., Coltharp, C., Amzel, L. M. & Zhang, J. Direct activation of Epac by sulfonylurea is isoform selective. Chem. Biol. 18, 243-251 (2011).
30. Hodson, D. J. et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity. J. Clin. Invest. 123, 4182-4194 (2013).
31. Rutter, G. A. & Hodson, D. J. Minireview: intraislet regulation of insulin secretion in humans. Mol. Endocrinol. 27, 1984-1995 (2013).
32. Quesada, I., Nadal, A. & Soria, B. Different effects of tolbutamide and diazoxide in alpha, beta-, and delta-cells within intact islets of Langerhans. Diabetes 48, 2390-2397 (1999).
33. Santos, R. M. et al. Widespread synchronous [Ca2+ ]i oscillations due to bursting electrical activity in single pancreatic islets. Pflugers Arch. 418, 417-422 (1991).
34. Head, W. S. et al. Connexin-36 gap junctions regulate in vivo first- and second-phase insulin secretion dynamics and glucose tolerance in the conscious mouse. Diabetes 61, 1700-1707 (2012).
35. Jonkers, F. C., Guiot, Y., Rahier, J. & Henquin, J. C. Tolbutamide stimulation of pancreatic beta-cells involves both cell recruitment and increase in the individual Ca(2+) response. Br. J. Pharmacol. 133, 575-585 (2001).
36. Gorostiza, P. & Isacoff, E. Y. Optical switches for remote and noninvasive control of cell signaling. Science 322, 395-399 (2008).
37. Velema, W. A., Szymanski, W. & Feringa, B. L. Photopharmacology: beyond proof of principle. J. Am. Chem. Soc. 136, 2178-2191 (2014).
38. Stein, M. et al. Azo-propofols: photochromic potentiators of GABA(A) receptors. Angew. Chem. Int. Ed. 51, 10500-10504 (2012).
39. Tochitsky, I. et al. Optochemical control of genetically engineered neuronal nicotinic acetylcholine receptors. Nat. Chem. 4, 105-111 (2012).
40. Mourot, A. et al. Rapid optical control of nociception with an ion-channel photoswitch. Nat. Methods 9, 396-402 (2012).
41. Lemoine, D. et al. Optical control of an ion channel gate. Proc. Natl Acad. Sci. USA 110, 20813-20818 (2013).
42. Velema, W. A. et al. Optical control of antibacterial activity. Nat. Chem. 5, 924-928 (2013).
43. Broichhagen, J., Jurastow, I., Iwan, K., Kummer, W. & Trauner, D. Optical control of acetylcholinesterase with a tacrine switch. Angew. Chem. Int. Ed. 53, 7657-7660 (2014).
44. Proks, P., Reimann, F., Green, N., Gribble, F. & Ashcroft, F. Sulfonylurea stimulation of insulin secretion. Diabetes 51(Suppl 3): S368-S376 (2002).
45. Caro, L. N., Moreau, C. J., Estrada-Mondragon, A., Ernst, O. P. & Vivaudou, M. Engineering of an artificial light-modulated potassium channel. PLoS ONE 7, e43766 (2012).
46. Reinbothe, T. M., Safi, F., Axelsson, A. S., Mollet, I. G. & Rosengren, A. H. Optogenetic control of insulin secretion in intact pancreatic islets with beta-cell- specific expression of Channelrhodopsin-2. Islets 6 (2014).
47. Ye, H., Daoud-El Baba, M., Peng, R. W. & Fussenegger, M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 332, 1565-1568 (2011).
48. Butler, P. C., Dry, S. & Elashoff, R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 33, 453-455 (2010).
49. Nauck, M. A. & Friedrich, N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 36(Suppl 2): S245-S252 (2013).
50. Rossger, K., Charpin-El-Hamri, G. & Fussenegger, M. A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat. Commun. 4, 2825 (2013).
51. Grossweiner, L. I., Jones, L. R., Grossweiner, J. B. & Rogers, B. H. G. The Science of Phototherapy: an Introduction (Springer, 2005).
52. Deisseroth, K. Optogenetics. Nat. Methods 8, 26-29 (2011).
53. Barretto, R. P. et al. Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. Nat. Med. 17, 223-228 (2011).
54. Kim, T. I. et al. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science 340, 211-216 (2013).
55. Seino, S., Shibasaki, T. & Minami, K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J. Clin. Invest. 121, 2118-2125 (2011).
56. Pocai, A. et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434, 1026-1031 (2005).
57. Martinez, C. H. & Dardonville, C. Rapid determination of ionization constants (pK a) by UV spectroscopy using 96-well microtiter plates. ACS Med. Chem. Lett. 4, 142-145 (2013).
58. Altomare, A. et al. SIR97: a new tool for crystal structure determination and refinement. J. Appl. Crystallogr. 32, 115-119 (1999).
59. Sheldrick, G. A short history of SHELX. Acta Crystallogr. Sect. A 64, 112-122 (2008).
60. Hodson, D. J. et al. ADCY5 couples glucose to insulin secretion in human islets. Diabetes 63, 3009-3021 (2014).